Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

Objective. CIGB-228 is a novel therapeutic vaccine consisting of HLA-restricted HPV16 E7 epitope adjuvated with VSSP. This trial was designed to evaluate the toxicity, safety, immunogenicity, HPV clearance, and lesion regression. Methods. Seven women were entered. All were HLA-A2 positive, had biops...

Descripción completa

Detalles Bibliográficos
Autores principales: Solares, Ana M., Baladron, Idania, Ramos, Thelvia, Valenzuela, Carmen, Borbon, Zaida, Fanjull, Sonia, Gonzalez, Leonardo, Castillo, Dagnelia, Esmir, Julio, Granadillo, Milaid, Batte, Aileen, Cintado, Alberto, Ale, Mayte, Fernandez de Cossio, Maria E., Ferrer, Annia, Torrens, Isis, Lopez-Saura, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scholarly Research Network 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118643/
https://www.ncbi.nlm.nih.gov/pubmed/21748025
http://dx.doi.org/10.5402/2011/292951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118643/
https://www.ncbi.nlm.nih.gov/pubmed/21748025
http://dx.doi.org/10.5402/2011/292951

Ejemplares similares